PL1673104T3 - Dostarczanie związków terapeutycznych do mózgu i do innych tkanek - Google Patents
Dostarczanie związków terapeutycznych do mózgu i do innych tkanekInfo
- Publication number
- PL1673104T3 PL1673104T3 PL04782579T PL04782579T PL1673104T3 PL 1673104 T3 PL1673104 T3 PL 1673104T3 PL 04782579 T PL04782579 T PL 04782579T PL 04782579 T PL04782579 T PL 04782579T PL 1673104 T3 PL1673104 T3 PL 1673104T3
- Authority
- PL
- Poland
- Prior art keywords
- brain
- tissues
- delivery
- therapeutic compounds
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/651,493 US7442372B2 (en) | 2003-08-29 | 2003-08-29 | Delivery of therapeutic compounds to the brain and other tissues |
EP04782579.9A EP1673104B2 (en) | 2003-08-29 | 2004-08-30 | Delivery of therapeutic compounds to the brain and other tissues |
PCT/US2004/028135 WO2005021064A2 (en) | 2003-08-29 | 2004-08-30 | Delivery of therapeutic compounds to the brain and other tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
PL1673104T3 true PL1673104T3 (pl) | 2014-03-31 |
PL1673104T5 PL1673104T5 (pl) | 2023-03-06 |
Family
ID=34217412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04782579.9T PL1673104T5 (pl) | 2003-08-29 | 2004-08-30 | Dostarczanie związków terapeutycznych do mózgu i do innych tkanek |
Country Status (12)
Country | Link |
---|---|
US (5) | US7442372B2 (pl) |
EP (1) | EP1673104B2 (pl) |
JP (1) | JP5819574B2 (pl) |
AU (1) | AU2004268645B2 (pl) |
CA (1) | CA2537238C (pl) |
CY (1) | CY1114815T1 (pl) |
DK (1) | DK1673104T4 (pl) |
ES (1) | ES2441612T5 (pl) |
PL (1) | PL1673104T5 (pl) |
PT (1) | PT1673104E (pl) |
SI (1) | SI1673104T2 (pl) |
WO (1) | WO2005021064A2 (pl) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6585971B1 (en) * | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
WO2006002283A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
PL1988823T3 (pl) * | 2006-02-09 | 2019-01-31 | Genzyme Corporation | Powolne dostarczanie dokomorowe |
EP2046435A4 (en) * | 2006-07-13 | 2012-06-27 | Medtronic Inc | METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES |
US8849372B2 (en) * | 2006-11-22 | 2014-09-30 | The General Hospital Corporation | Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent |
US20080140056A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Method for delivering large molecules to the brain |
WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
CN101631794B (zh) * | 2007-01-18 | 2013-01-02 | 建新公司 | 包含氨基氧基基团的寡糖及其轭合物 |
SI2158322T1 (sl) * | 2007-06-06 | 2017-10-30 | Genzyme Corporation | Genska terapija za bolezni lizosomskega shranjevanja |
US20090048648A1 (en) * | 2007-08-17 | 2009-02-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Self-sterilizing device |
US8114346B2 (en) * | 2007-08-17 | 2012-02-14 | The Invention Science Fund I, Llc | Event-triggered ultraviolet light sterilization of surfaces |
US8029740B2 (en) * | 2008-07-11 | 2011-10-04 | The Invention Science Fund I, Llc | Event-triggered self-sterilization of article surfaces |
US8753304B2 (en) | 2007-08-17 | 2014-06-17 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter |
US8460229B2 (en) | 2007-08-17 | 2013-06-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states |
US8706211B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having self-cleaning surfaces |
US8162924B2 (en) | 2007-08-17 | 2012-04-24 | The Invention Science Fund I, Llc | System, devices, and methods including actively-controllable superoxide water generating systems |
US8734718B2 (en) | 2007-08-17 | 2014-05-27 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component |
US8366652B2 (en) | 2007-08-17 | 2013-02-05 | The Invention Science Fund I, Llc | Systems, devices, and methods including infection-fighting and monitoring shunts |
US8702640B2 (en) | 2007-08-17 | 2014-04-22 | The Invention Science Fund I, Llc | System, devices, and methods including catheters configured to monitor and inhibit biofilm formation |
US8647292B2 (en) | 2007-08-17 | 2014-02-11 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states |
AU2008290217B2 (en) * | 2007-08-20 | 2013-09-05 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
US20100266569A1 (en) * | 2007-11-15 | 2010-10-21 | Mark Zylka | Prostatic acid phosphatase for the treatment of pain |
ES2830350T3 (es) | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
US20120041287A1 (en) | 2008-12-04 | 2012-02-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems, devices, and methods including implantable devices with anti-microbial properties |
EP2384168B1 (en) | 2008-12-04 | 2014-10-08 | Searete LLC | Actively-controllable sterilizing excitation delivery implants |
US8585627B2 (en) | 2008-12-04 | 2013-11-19 | The Invention Science Fund I, Llc | Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure |
BR122020010601B8 (pt) | 2008-12-16 | 2021-07-27 | Genzyme Corp | conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas |
ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
HRP20211992T1 (hr) * | 2009-08-28 | 2022-04-01 | Icahn School Of Medicine At Mount Sinai | Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
WO2011163649A2 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc | Methods and compositions for cns delivery of iduronate-2-sulfatase |
PT3626258T (pt) * | 2010-06-25 | 2021-10-19 | Shire Human Genetic Therapies | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase |
US9320711B2 (en) * | 2010-06-25 | 2016-04-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of heparan N-sulfatase |
WO2011163651A2 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE |
MX2013000324A (es) * | 2010-06-25 | 2013-02-01 | Shire Human Genetic Therapies | Tratamiento del sindrome de sanfilippo tipo b. |
RU2626514C2 (ru) * | 2010-06-25 | 2017-07-28 | Шир Хьюман Дженетик Терапис, Инк. | Доставка к цнс лечебных агентов |
PL3626257T3 (pl) | 2010-06-25 | 2022-03-28 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania arylosulfatazy a do oun |
JP2012062312A (ja) * | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
LT3272861T (lt) | 2011-01-20 | 2020-03-25 | Protalix Ltd. | Alfa-galaktozidazės kompozicijos |
CA2852027A1 (en) * | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
US9101678B2 (en) | 2011-11-03 | 2015-08-11 | Elwha Llc | Heat-sanitization of surfaces |
CN104114686A (zh) * | 2011-11-07 | 2014-10-22 | 夏尔人类遗传性治疗公司 | Sanfilippo综合征的生物标志物及其用途 |
WO2013081706A1 (en) * | 2011-12-02 | 2013-06-06 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
EP2793922B1 (en) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
WO2013096912A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
JP6433424B2 (ja) * | 2012-07-31 | 2018-12-05 | バイオアシス テクノロジーズ インコーポレイテッド | 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法 |
CN107865968B (zh) * | 2012-08-03 | 2021-03-05 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗溶酶体贮积症的环糊精 |
PL2925776T3 (pl) | 2012-11-27 | 2018-11-30 | Biomarin Pharmaceutical Inc. | Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania |
US20150313971A1 (en) * | 2012-12-07 | 2015-11-05 | Shire Human Genetic Therapies | Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia |
EP2981551B1 (en) | 2013-02-20 | 2020-06-03 | Valerion Therapeutics, LLC | Methods and compositions for treatment of pompe disease |
CA2912678C (en) * | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
EP3088518A4 (en) | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
TWI752907B (zh) | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
MX2017015879A (es) | 2015-06-10 | 2018-08-16 | Vtesse Inc | Composiciones de hidroxipropil beta-ciclodextrina y metodos. |
CN114409783A (zh) | 2015-06-24 | 2022-04-29 | Jcr制药股份有限公司 | 通过血脑屏障的抗人转铁蛋白受体抗体 |
CN107849150B (zh) | 2015-06-24 | 2021-12-14 | Jcr制药股份有限公司 | 含有bdnf的融合蛋白 |
JP2018538008A (ja) | 2015-11-06 | 2018-12-27 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ |
JP7109369B2 (ja) | 2016-02-24 | 2022-07-29 | バイオマリン ファーマシューティカル インコーポレイテッド | ターゲティングされた治療用リソソーム酵素融合タンパク質、関連する製剤、およびその使用 |
KR20230125339A (ko) | 2016-04-15 | 2023-08-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
KR102657707B1 (ko) * | 2016-06-02 | 2024-04-15 | 에이디에스 테라퓨틱스 엘엘씨 | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 |
US11504435B2 (en) | 2016-06-13 | 2022-11-22 | The University Of North Carolina At Chapel Hill | Optimized CLN1 genes and expression cassettes and their use |
CA3052936A1 (en) | 2016-12-26 | 2018-07-05 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein of bdnf and anti-transferrin receptor antibody |
JP6956741B2 (ja) | 2016-12-26 | 2021-11-02 | Jcrファーマ株式会社 | 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体 |
US11723865B2 (en) | 2017-02-08 | 2023-08-15 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
US11541005B2 (en) | 2017-02-08 | 2023-01-03 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
BR112020005249A2 (pt) | 2017-09-22 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 酵素補充療法用酵素を含む融合タンパク質 |
US11730767B2 (en) | 2018-02-23 | 2023-08-22 | Regeneration Biomedical, Inc. | Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system |
EP3670652A1 (en) * | 2018-12-18 | 2020-06-24 | NEUWAY Pharma GmbH | Vlp for the treatment of a lysosomal storage disease |
ES2933275T3 (es) | 2018-12-18 | 2023-02-03 | Neuway Pharma Gmbh | Un sistema de suministro de fármacos novedoso y métodos para proporcionar los mismos |
US20220023434A1 (en) | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
US11446084B2 (en) | 2019-07-12 | 2022-09-20 | Neuralink Corp. | Laser drilling of pia mater |
CA3152521A1 (en) | 2019-08-29 | 2021-03-04 | Biomarin Pharmaceutical Inc. | Methods for treating cln2 disease in pediatric subjects |
CA3164707A1 (en) | 2020-02-03 | 2021-08-12 | Ana Maria Garcia Collazo | Combination therapy for treating mps1 |
US20240043473A1 (en) * | 2021-02-09 | 2024-02-08 | Phoenix Nest Inc. | Nootropic peptides for treating lysosomal storage diseases |
US11958917B2 (en) | 2022-02-18 | 2024-04-16 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
JPS5883691A (ja) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | 1′,2′−ジアシル−(6r,s)−5,6,7,8−テトラヒドロ−l−ビオプテリンおよびその製法 |
CH651755A5 (en) | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
JPS5976086A (ja) | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
JPS60178887A (ja) | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−ビオプテリンの製造法 |
JPS60199889A (ja) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−エリスロ−ビオプテリンの硫酸塩およびその製法 |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
DE3437944A1 (de) | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt |
US4713454A (en) | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4937342A (en) | 1987-11-30 | 1990-06-26 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing BH4 and its derivatives |
US6149909A (en) | 1995-06-23 | 2000-11-21 | Women's And Children's Hospital | Synthetic α-L-iduronidase and genetic sequences encoding same |
JP2534423B2 (ja) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
DE4308739C1 (de) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
US5945452A (en) | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
US5753656A (en) | 1994-08-05 | 1998-05-19 | Suntory Limited | Method for treating spinocerebellar degeneration |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
ATE426031T1 (de) | 1995-09-14 | 2009-04-15 | Virginia Tech Intell Prop | Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen |
US6002067A (en) | 1996-05-20 | 1999-12-14 | The University Of British Columbia | Transgenic mouse model for iduronidase deficiency and methods of making and using same |
US20020076782A1 (en) | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
US6458574B1 (en) † | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US5922713A (en) | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
JP4306825B2 (ja) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
AU4072499A (en) * | 1998-05-13 | 1999-11-29 | Harbor-Ucla | Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US6200758B1 (en) | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
JP2002539257A (ja) | 1999-03-19 | 2002-11-19 | イーノス・ファーマシューティカルス・インコーポレーテッド | 薬剤の脳内生物学的利用率の増加 |
US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
US6569661B1 (en) | 1999-11-12 | 2003-05-27 | Biomarin Pharmaceutical Inc. | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
AU782020B2 (en) * | 1999-11-12 | 2005-06-30 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US6585971B1 (en) | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
WO2001036603A2 (en) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
US6972124B2 (en) * | 2000-05-01 | 2005-12-06 | Biomarin Pharmaceuticals Inc. | Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
US6544994B2 (en) | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
EP3449934B1 (en) | 2000-07-18 | 2020-05-20 | Duke University | Treatment of glycogen storage disease type ii |
US20050119270A1 (en) | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
AU2001280215B9 (en) | 2000-08-31 | 2007-03-22 | Asubio Pharma Co., Ltd. | Process for Production of Biopterin Compound |
ES2300439T3 (es) * | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
AU2002317700A1 (en) † | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
US20030007961A1 (en) | 2001-06-22 | 2003-01-09 | Wilburn Michael D. | Orthomolecular vitamin E derivatives |
US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
AU2003224880A1 (en) | 2002-04-05 | 2003-10-27 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
US20030198620A1 (en) | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
EP1503788B1 (en) | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
DE10260263A1 (de) | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
WO2004091475A2 (en) | 2003-04-16 | 2004-10-28 | Yeda Research And Development Co. Ltd. | Gaucher disease drugs and methods of identifying same |
CA2525236C (en) | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
EP2436379A1 (en) | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
-
2003
- 2003-08-29 US US10/651,493 patent/US7442372B2/en active Active
-
2004
- 2004-08-30 SI SI200432119T patent/SI1673104T2/sl unknown
- 2004-08-30 WO PCT/US2004/028135 patent/WO2005021064A2/en active Application Filing
- 2004-08-30 PT PT47825799T patent/PT1673104E/pt unknown
- 2004-08-30 DK DK04782579.9T patent/DK1673104T4/da active
- 2004-08-30 PL PL04782579.9T patent/PL1673104T5/pl unknown
- 2004-08-30 AU AU2004268645A patent/AU2004268645B2/en active Active
- 2004-08-30 ES ES04782579T patent/ES2441612T5/es active Active
- 2004-08-30 CA CA2537238A patent/CA2537238C/en active Active
- 2004-08-30 JP JP2006524936A patent/JP5819574B2/ja active Active
- 2004-08-30 EP EP04782579.9A patent/EP1673104B2/en active Active
- 2004-08-30 US US11/630,446 patent/US9044473B2/en active Active
-
2012
- 2012-02-17 US US13/399,787 patent/US9089566B2/en not_active Expired - Lifetime
-
2014
- 2014-01-09 CY CY20141100019T patent/CY1114815T1/el unknown
-
2015
- 2015-02-05 US US14/615,098 patent/US9572870B2/en not_active Expired - Lifetime
-
2017
- 2017-01-06 US US15/400,289 patent/US11040088B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2004268645A1 (en) | 2005-03-10 |
CA2537238C (en) | 2015-01-06 |
US20090017005A1 (en) | 2009-01-15 |
CY1114815T1 (el) | 2016-12-14 |
US20150150799A1 (en) | 2015-06-04 |
US9044473B2 (en) | 2015-06-02 |
US11040088B2 (en) | 2021-06-22 |
CA2537238A1 (en) | 2005-03-10 |
SI1673104T2 (sl) | 2022-01-31 |
JP2007504166A (ja) | 2007-03-01 |
PL1673104T5 (pl) | 2023-03-06 |
JP5819574B2 (ja) | 2015-11-24 |
AU2004268645B2 (en) | 2010-02-18 |
US9572870B2 (en) | 2017-02-21 |
WO2005021064A2 (en) | 2005-03-10 |
DK1673104T3 (da) | 2014-01-20 |
US9089566B2 (en) | 2015-07-28 |
EP1673104B2 (en) | 2021-10-27 |
DK1673104T4 (da) | 2022-01-17 |
EP1673104A2 (en) | 2006-06-28 |
US20170182134A1 (en) | 2017-06-29 |
US20120148558A1 (en) | 2012-06-14 |
WO2005021064A3 (en) | 2005-08-25 |
ES2441612T5 (es) | 2022-04-04 |
PT1673104E (pt) | 2014-01-15 |
EP1673104A4 (en) | 2009-08-12 |
EP1673104B1 (en) | 2013-10-09 |
SI1673104T1 (sl) | 2014-02-28 |
US7442372B2 (en) | 2008-10-28 |
US20050048047A1 (en) | 2005-03-03 |
ES2441612T3 (es) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1089107A1 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
SI1673104T1 (sl) | Dostava terapevtskih spojin moĹľganom in drugim tkivom | |
EP1638605A4 (en) | DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE | |
EP1737453A4 (en) | METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS | |
EP1567157A4 (en) | METHODS OF USE AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE SYNDROMES | |
HK1097256A1 (en) | Pyrizdazine derivatives and their use as therapeutic agents | |
GB0324761D0 (en) | Use of compounds in therapy | |
AU2002341558A1 (en) | Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream | |
IL173351A0 (en) | Therapy of ocular disorders | |
IL176227A0 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
AU2003286741A8 (en) | Methods and compositions for diagnosis and therapy of parkin-associated disorders | |
EP1680145A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
GB0305150D0 (en) | Use of therapeutic compounds | |
PL1670482T3 (pl) | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego | |
GB0213869D0 (en) | The treatment of pain | |
AU2003247140A1 (en) | Delivering compounds to the brain by modifying properties of the bbb and cerebral circulation | |
AU2003268484A8 (en) | Delivery of therapeutics to the brain and spinal cord | |
AU2003255843A1 (en) | 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain | |
IL164951A0 (en) | The treatment of pain with lfendropil | |
GB0312844D0 (en) | Use of compounds in medicine | |
GB0325957D0 (en) | The treatment of pain | |
IL174968A0 (en) | The use of ifenprodil in the treatment of pain | |
GB0322014D0 (en) | The treatment of pain | |
GB0303533D0 (en) | Delivery of agents to the body | |
GB0415267D0 (en) | The treatment of pain |